Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 316-323

  Meijer, Tineke W H ^a   Schuurbiers, Olga C J ^a   Kaanders, Johannes H A M ^a   Looijen Salamon, Monika G ^a   de Geus Oei, Lioe Fee ^a   Verhagen, Ad F T M ^a   Lok, Jasper ^a   van der Heijden, Henricus F M ^a   Rademakers, Saskia E ^a   Span, Paul N ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinomas; GLUT1; MCT4; Metabolism; NSCLC; Prognosis; Squamous cell carcinomas

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARRIER PROTEIN; GLUCOSE TRANSPORTER 1; PROTEIN MCT4; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AGED; ANAEROBIC METABOLISM; ARTICLE; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL HYPOXIA; DISEASE SPECIFIC SURVIVAL; FEMALE; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METABOLISM; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; UPREGULATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860537584     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.006     Document Type: Article

References (41)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Kelsey C.R., Light K.L., Marks L.B. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys 2006, 65:1097-1105.
3. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007, 62:214-219.
4. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., Krabbe P.F., Frielink C., Verhagen A.F., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007, 55:79-87.
5. Schuurbiers O.C., Kaanders J.H., van der Heijden H.F., Dekhuijzen R.P., Oyen W.J., Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009, 4:761-767.
6. Bussink J., Kaanders J.H., van der Graaf W.T., Oyen W.J. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011, 8:233-242.
7. Minami K., Saito Y., Imamura H., Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
8. Busk M., Horsman M.R., Jakobsen S., Bussink J., van der Kogel A., Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008, 35:2294-2303.
9. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009, 121:29-40.
10. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008, 49:24S-42S.
11. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654-662.
12. Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008, 2:41-53.
13. Ullah M.S., Davies A.J., Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-9037.
14. Moon E.J., Brizel D.M., Chi J.T., Dewhirst M.W. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007, 9:1237-1294.
15. Schneiderhan W., Scheler M., Holzmann K.H., Marx M., Gschwend J.E., Bucholz M., et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 2009, 58:1391-1398.
16. Sattler U.G., Meyer S.S., Quennet V., Hoerner C., Knoerzer H., Fabian C., et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 2010, 94:102-109.
17. Rijken P.F., Bernsen H.J., Peters J.P., Hodgkiss R.J., Raleigh J.A., van der Kogel A.J. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 2000, 48:571-582.
18. Bussink J., Kaanders J.H., Rijken P.F., Martindale C.A., van der Kogel A.J. Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br J Cancer 1998, 77:57-64.
19. Rademakers S.E., Lok J., van der Kogel A.J., Bussink J., Kaanders J.H. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011, 11:167.
20. Rademakers S.E., Rijken P.F., Peeters W.J., Nijkamp M.M., Barber P.R., van der Laak J., et al. Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers. Cell Oncol 2011, 34:119-129.
21. Rijken P.F., Bernsen H.J., van der Kogel A.J. Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 1995, 50:141-153.
22. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
23. Andersen S., Eilertsen M., Donnem T., Al-Shibli K., Al-Saad S., Busund L.T., et al. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011, 72:294-302.
24. Brown R.S., Leung J.Y., Kison P.V., Zasadny K.R., Flint A., Wahl R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999, 40:556-565.
25. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 2000, 27:1778-1785.
26. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998, 11:437-443.
27. Mamede M., Higashi T., Kitaichi M., Ishizu K., Ishimori T., Nakamoto Y., et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7:369-379.
28. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in Stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
29. Semenza G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009, 19:12-16.
30. Semenza G.L. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 2008, 118:3835-3837.
31. Marom E.M., Aloia T.A., Moore M.B., Hara M., Herndon J.E., Harpole D.H., et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 2001, 33:99-107.
32. van Baardwijk A., Dooms C., van Suylen R.J., Verbeken E., Hochstenbag M., Dehing-Oberije C., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007, 43:1392-1398.
33. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
34. Jadvar H., Alavi A., Gambhir S.S. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009, 50:1820-1827.
35. Izumi H., Takahashi M., Uramoto H., Nakayama Y., Oyama T., Wang K.Y., et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011, 102:1007-1013.
36. Kennedy K.M., Dewhirst M.W. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010, 6:127-148.
37. Quennet V., Yaromina A., Zips D., Rosner A., Walenta S., Baumann M., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006, 81:130-135.
38. Mueller-Klieser W., Walenta S. Geographical mapping of metabolites in biological tissue with quantitative bioluminescence and single photon imaging. Histochem J 1993, 25:407-420.
39. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
40. Gallagher S.M., Castorino J.J., Philp N.J. Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration. Am J Physiol Cell Physiol 2009, 296:C414-C421.
41. Gallagher S.M., Castorino J.J., Wang D., Philp N.J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007, 67:4182-4189.